Sanoosa

Executive Summary

Sanoosa Pty Ltd is an Australian preclinical biotech leveraging computational drug design to develop small-molecule therapeutics for chronic inflammatory diseases, cancer, and COVID-19. Founded in 2020 and based in Melbourne, the company targets historically undruggable protein-protein and RNA-protein interactions, aiming to create oral agents with novel mechanisms of action. Its platform combines in silico screening and rational design to accelerate discovery of first-in-class candidates. With a lean team of 10-50 employees and no disclosed funding, Sanoosa operates at an early stage but addresses high-value therapeutic areas with significant unmet need.

Upcoming Catalysts (preview)

• Q4 2026Lead Optimization Milestone in Inflammatory Disease Program60% success
• Q1 2027Series A Financing Round50% success
• Q3 2027IND-Enabling Studies Initiation for COVID-19 Candidate30% success